Table 3.
Crude (Univariate Analysis) and Adjusted (Multivariate Model) Effect of Rituximab and Baseline Characteristics on Progression-free Survival in 193 Patients With Stage II/III/IV Nodular Lymphocyte-predominant Hodgkin Lymphoma Who Received Chemotherapy
| Univariable Analysis | Multivariable Model | ||||||
|---|---|---|---|---|---|---|---|
| CHEMO (n = 81) | R-CHEMO (n = 112) | P value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age at diagnosis (y), median (IQR) | 42 (35–53) | 49 (39–59) | 0.014 | 1.0 (1.0-1.0) | 0.915 | - | |
| Stage, n (%) | 0.028 | ||||||
| II | 53 (65.4%) | 55 (49.1%) | Ref | Ref | - | - | |
| III–IV | 28 (34.6%) | 57 (50.9%) | 2.0 (1.1-3.6) | 0.030 | - | - | |
| Hemoglobin (g/dL), median (IQR) | 14.4 (13.2–15.4) | 14.3 (13.1–15.2) | 0.648 | 0.9 (0.7-1.1) | 0.217 | - | - |
| Lymphocytes, n (%) | >0.90 | ||||||
| ≥8% | 73 (98.7%) | 100 (98.0%) | Ref | Ref | Ref | Ref | |
| <8% | 1 (1.3%) | 2 (2.0%) | 4.5 (1.1-18.7) | 0.041 | 2.8 (0.6-13.3) | 0.184 | |
| Spleen involvement, n (%) | 0.239 | ||||||
| No | 71 (87.7%) | 90 (80.4%) | Ref | Ref | Ref | Ref | |
| Yes | 10 (12.3%) | 22 (19.6%) | 3.9 (2.0-7.6) | <0.001 | 3.2 (1.4-7.6) | 0.007 | |
| Bulky, n (%) | 0.386 | ||||||
| No | 72 (94.7%) | 80 (90.9%) | Ref | Ref | Ref | Ref | |
| Yes | 4 (5.3%) | 8 (9.1%) | 2.5 (0.9-7.1) | 0.085 | 3.4 (1.1-10.7) | 0.034 | |
| B symptoms, n (%) | 0.193 | ||||||
| No | 74 (91.4%) | 95 (84.8%) | Ref | Ref | Ref | Ref | |
| Yes | 7 (8.6%) | 17 (15.2%) | 2.2 (1.1-4.6) | 0.034 | 1.9 (0.8-4.7) | 0.155 | |
| Albumin, n (%) | 0.411 | - | |||||
| ≥4 g/dL | 56 (84.9%) | 72 (78.3%) | Ref | Ref | - | - | |
| <4 g/dL | 10 (15.1%) | 20 (21.7%) | 0.9 (0.3-2.3) | 0.804 | - | - | |
| Rituximab, n (%) | |||||||
| No | - | - | Ref | Ref | Ref | Ref | |
| Yes | - | - | 0.5 (0.3-1.0) | 0.037 | 0.4 (0.2-0.8) | 0.015 | |
CI = confidence interval; HR = hazard ratio; IQR = interquartile range.